We are InBody,

a worldwide leader in body composition technology.

In the early 1990s, the founder and chairman of our headquarters at InBody Co., Ltd. in Seoul, South Korea, Dr. Kichul Cha, recognized that the available BIA devices were limited and faulty. They were often inaccurate, and from a medical standpoint, the data sets were heavily reliant on empirical estimations that may not represent all patients. This approach might lead to inaccurate representations of patient health status and be less sensitive to treatment progress over time. Drawing from his background in mechanical engineering, he set to work to design something better.

In 1996, he founded InBody. Two years later, the first InBody device was born. InBody’s 4 core technologies set us apart from other BIA devices. InBody has direct segmental measurement that separately measures the trunk, arms, and legs, which is important for accurate body composition. The use of multiple frequencies measures total body water, which includes fluid both inside and outside of body cells. Our 8-point tactile electrode system provides 99% reproducibility across tests. InBody does not use empirical estimations in measured values, and we are correlated at 98% with DEXA. InBody was also validated in diverse populations

Today, InBody has grown from a small biotech startup in South Korea to a multinational corporation with branches and distributors in more than 80 countries. Because of the growing demand for our devices in the critical ill and the over 6000 peer-reviewed publications involving InBody, InBody BWA Inc was born.

BWA’s sole mission is to improve lives through improved standard of care for the critically ill. Guided by our body water analysis, clinicians and researchers will be bringing more precision to patient care.

Our job now is to simply share – InBody BWA everywhere.

Vision and Mission

Validated – Trusted – Supported

Founded by Dr. Cha at Harvard Medical School in the early 1990s, InBody has grown into a global leader in body composition and fluid quantification. We are the only bioelectrical impedance analysis (BIA) device validated at 98% to DEXA by Mayo Clinic and are used in nearly 6,000 peer-reviewed studies worldwide. We believe patient health can be elevated by quantifying muscle, fat, mineral, and water. Anthropometric data can be used to help evaluate the efficacy of intervention, monitor and manage disease status, and encourage compliance in an individualized, non-invasive, and granular way. Beyond the device, we continue to update our database with the latest research across many disciplines, which has helped us connect researchers who go on to collaborate and share data to further expand their field. We can assist clinicians with interpreting the results or connecting with other health professionals caring for similar patient populations.

Message from the founder and creator of InBody, Dr. Kichul Cha

“Since InBody established in 1996, we have strived to operate as an excellent, 21st-century company. By fulfilling our corporate mission of contributing to society with world-leading technology. We will continue to support the growth of society with high-value-added products and services, facing all challenges and meeting your expectations with a deep sense of responsibility. InBody continues to grow, as we don’t look for big success, but small achievements. InBody is dedicated to inspiring and leading people to live a healthier life. Going forward, we will continue to follow our motto — “Makes Life Better” — while steadfastly adhering to our guiding principles of passion, effort, and innovation.”

History of InBody

Early 1990's

Dr. Kichul Cha recognised BIA devices were inaccurate, making them useless to the medical industry.


InBody was founded in South Korea. Products feature direct segmental multi-frequency bioelectrical impedance analysis (DSM-BIA) and an eight-point tactile electrode system to measure an individual’s body composition without the use of empirical data.


InBody established its first overseas subsidiary in Beverly Hills, California.
The second overseas subsidiary was established in Tokyo, Japan in this year as well.
InBody technology is FDA approved and results have been validated by research.

2008 - 2011

PAPS(Physical Activity Promotion System) was introducted to the Ministry of Education in Korea. In this period, over 3,200 units of InBody products were installed in elementary, middle, and high school.


The InBody 570, capable of measuring segmental fat analysis including visceral fat level, is released.


The InBody 770, a new research-grade body composition analyser is launched and the InBody 570 wins the Red Dot Design Award.


iF DESIGN AWARD is given to the InBody 770.

InBody receives the 2015 Foreign Direct Investment Award from the Los Angeles Chamber of Commerce during World Trade Week.

InBody BAND and InLab win CES 2015 Innovation Award for wearable technologies.

InBody unveiled the InBody BAND, the world’s first wearable body composition device.


InBody expanded its business to global market.
In this year, InBody Europe, InBody Asia, InBody India were established.
Also, InBody launched cloud-based data software, LookinBody Web.


InBody Mexico was established.
InBody is contributing to the medical field in the global market through 7 overseas subsidiaries.


InBody presents A New Standard of Innovation, InBody970 and BWA2.0.


InBody BWA, Inc. was established In Pennsylvania to focus on the clinical care and research of chronic disease.

Global Network​

As a global enterprise, InBody is located in over 80 countries around the world, and exports to about 100 countries. Aside from the headquarters office, InBody Co., Ltd, located in South Korea, 9 subsidiaries and branches are located in USA, Europe, Mexico, China, Japan, India, and Malaysia. ​

Contact us

We’d love to hear from you.
Use the form below to send us a message!

Privacy Policy: No mobile information will be shared with third parties/affiliates for marketing/promotional purposes. All the above categories exclude text messaging originator opt-in data and consent; this information will not be shared with any third parties.